Immune checkpoint inhibitors in patients with cancers of unknown primary

Collectively, cancers of unknown primary (CUP) account for 2 –5% of all diagnosed cancers and are often associated with a poor prognosis [1]. Previous clinical trials using conventional chemotherapy in CUP patients did not yield the anticipated survival improvements [2]. Despite the transformative impact of precision medicine in various tumour types, addres sing CUP remained elusive despite exploring site-specific therapy and targeted therapies [3]. The former was guided by the traditional oncology approach of targeting the organ of origin however, a meta-analysis of the studies evaluating site-specific therapy did not support this approach [4].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Editorial Source Type: research